Loading...
XSHG
600351
Market cap621mUSD
Jul 10, Last price  
6.26CNY
1D
2.79%
1Q
-6.85%
Jan 2017
-36.64%
IPO
148.41%
Name

Yabao Pharmaceutical Group Co Ltd

Chart & Performance

D1W1MN
XSHG:600351 chart
P/E
13.54
P/S
1.93
EPS
0.46
Div Yield, %
4.93%
Shrs. gr., 5y
-2.02%
Rev. gr., 5y
-2.95%
Revenues
2.24b
-16.60%
741,299,852986,054,9751,254,651,5871,488,266,4311,181,821,8531,662,746,2841,266,573,1811,624,882,7811,889,657,4282,065,627,0711,806,110,1692,558,514,6212,918,099,2193,041,915,8982,602,423,1062,763,962,4802,718,134,7842,909,765,2552,686,037,5672,240,063,505
Net income
320m
+31.86%
21,822,21045,059,57785,455,888129,294,105144,301,943186,430,628112,287,478118,195,521170,121,898222,090,41222,521,866200,206,386273,335,27013,906,944107,369,058187,089,428104,655,074199,585,795242,688,462320,013,385
CFO
574m
+21.64%
11,590,939105,685,653102,899,172368,564,04418,565,50940,726,841056,801,873178,626,984143,466,388155,954,179161,726,197426,601,444425,169,570380,960,275437,503,470460,462,582497,553,579471,694,572573,765,714
Dividend
May 30, 20250.3 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Yabao Pharmaceutical Group Co., Ltd researches, develops, manufactures, and sells Chinese and Western medicines, and pharmaceutical packaging materials in China and internationally. It provides pediatric products, cardiovascular and cerebrovascular products, endocrine products, women's health products, patches, and general health products. Yabao Pharmaceutical Group Co., Ltd was founded in 1978 and is based in Beijing, China.
IPO date
Sep 26, 2002
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT